Halozyme Therapeutics, Inc.HALONASDAQ
Loading
Year-over-year revenue growth rate
5Y CAGR
-20.4%/yr
Long-term compound
Percentile
P77
Within normal range
vs 5Y Ago
0.3x
Contraction
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 27.52% |
| Q3 2025 | 8.76% |
| Q2 2025 | 22.98% |
| Q1 2025 | -11.12% |
| Q4 2024 | 2.73% |
| Q3 2024 | 25.39% |
| Q2 2024 | 18.11% |
| Q1 2024 | -14.85% |
| Q4 2023 | 6.48% |
| Q3 2023 | -2.26% |
| Q2 2023 | 36.32% |
| Q1 2023 | -10.66% |
| Q4 2022 | -13.15% |
| Q3 2022 | 37.15% |
| Q2 2022 | 29.92% |
| Q1 2022 | 14.98% |
| Q4 2021 | -11.94% |
| Q3 2021 | -15.11% |
| Q2 2021 | 53.28% |
| Q1 2021 | -26.85% |
| Q4 2020 | 86.33% |
| Q3 2020 | 18.28% |
| Q2 2020 | 117.80% |
| Q1 2020 | -52.76% |
| Q4 2019 | 16.08% |
| Q3 2019 | 18.09% |
| Q2 2019 | -31.26% |
| Q1 2019 | -5.45% |
| Q4 2018 | 135.69% |
| Q3 2018 | -27.40% |
| Q2 2018 | 14.03% |
| Q1 2018 | -83.71% |
| Q4 2017 | 197.44% |
| Q3 2017 | 88.83% |
| Q2 2017 | 14.14% |
| Q1 2017 | -24.19% |
| Q4 2016 | 22.45% |
| Q3 2016 | -4.45% |
| Q2 2016 | -21.56% |
| Q1 2016 | -18.63% |